文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

胃肠道恶性肿瘤中DPYD与UGT1A1药物基因组检测的临床实施综述

DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.
PubMed 文献 · Pharmacotherapy · 2020-10-19

本文综述胃肠道恶性肿瘤中DPYD-氟尿嘧啶/卡培他滨和UGT1A1-伊立替康两对药物-基因对的药物基因组学特征及减少严重不良事件的临床证据。文章还讨论临床实施考虑,包括实验室工作流程、电子健康记录整合、利益相关者参与和提供者教育,并描述探索性PGx标志物。随着PGx知识快速发展,药师将在临床实施PGx检测中发挥关键作用。

要点

  • DPYD与UGT1A1检测可预测胃肠道肿瘤化疗严重毒性
  • 实施需优化实验室流程与电子健康记录整合
  • 药师在PGx检测临床落地中承担关键角色

核心结论

  • DPYD和UGT1A1药物基因组检测有助于预测氟尿嘧啶类和伊立替康的严重不良事件。

研究设计与样本

  • 本文为综述,讨论胃肠道恶性肿瘤中DPYD-氟尿嘧啶/卡培他滨和UGT1A1-伊立替康的药物基因组学证据及临床实施考虑。

主要发现

  • 氟尿嘧啶类和伊立替康仍是许多胃肠道肿瘤化疗的基石。
  • DPYD和UGT1A1的PGx特征可用于预测治疗反应和毒性。
  • 利用PGx可帮助临床医生预见药物耐受性,减少治疗中断或延迟。

临床怎么用

  • 临床实施需考虑优化实验室工作流程、电子健康记录整合、利益相关者参与和提供者教育。
  • 药师可利用药理学知识和临床技能在临床实施PGx检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gastrointestinal (GI) malignancies are among the most commonly diagnosed cancers worldwide. Despite the introduction of targeted and immunotherapy agents in the treatment landscape, cytotoxic agents, such as fluoropyrimidines and irinotecan, remain as the cornerstone of chemotherapy for many of these tumors. Pharmacogenetics (PGx) is a rapidly evolving field that accounts for interpatient variability in drug metabolism to predict therapeutic response and toxicity. Given the significant incidence of severe treatment-related adverse events associated with cytotoxic agents, utilizing PGx can allow clinicians to better anticipate drug tolerability while minimizing treatment interruptions or delays. In this review, the PGx profiles of drug-gene pairs with potential impact in GI malignancy therapy - DPYD-5-fluorouracil/capecitabine and UGT1A1-irinotecan - and the available clinical evidence of their roles in reducing severe adverse events are discussed. Considerations for clinical implementation, such as optimal laboratory workflows, electronic health record integration, and stakeholder engagement, as well as provider education, are addressed. Last, exploratory PGx markers in GI malignancy treatment are described. As the PGx knowledge base rapidly evolves, pharmacists will be vital in leveraging their pharmacology knowledge and clinical skills to implement PGx testing in the clinic.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Varughese LA, Lau-Min KS, Cambareri C, et al. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation. Pharmacotherapy. 2020. PMID: 32985005. doi:10.1002/phar.2463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。